Princeton-based BioCentriq, a cell therapy contract development and manufacturing organization (CDMO), on Tuesday announced a strategic partnership with Orchestra Life Sciences (OLS), a premier technical consultancy firm specializing in advanced therapy manufacturing solutions.
BioCentriq said the collaboration supports its recently announced expansion in Princeton and focuses on its $12M CAPEX investment for facility optimization and digital integration to enhance the site’s cell therapy development, GMP manufacturing and testing capabilities.
Orchestra Life Sciences will provide comprehensive technical expertise and strategic support for BioCentriq’s new 60,000 sq. ft. Princeton facility, which was announced in December 2024.
The partnership encompasses multiple strategic initiatives, including the implementation of advanced manufacturing technologies, development of a fully integrated digital ecosystem, and optimization of facility design to meet the stringent regulatory requirements of cell therapy production under US FDA and EU GMP Annex 1.
This collaboration strengthens BioCentriq’s position as a leading provider of cell therapy manufacturing solutions while ensuring operational excellence across all aspects of their service.
The partnership leverages Orchestra Life Sciences’ proven track record in advanced therapy facility design and infrastructure optimization.
“This partnership with Orchestra Life Sciences represents another significant step in our commitment to delivering best-in-class cell therapy manufacturing solutions,” Syed Husain, chairman and CEO of BioCentriq said. “Their expertise in facility design, engineering solutions, and operational excellence aligns perfectly with our vision for creating a cutting-edge manufacturing center that will serve the evolving clinical- and commercial-stage needs of our clients. This collaboration will enable us to accelerate our capability and bring additional infrastructure and capacity to industry in support of innovative cell therapies.”
The collaboration will enhance BioCentriq’s ability to provide comprehensive development and manufacturing services for cell therapy innovators. Orchestra Life Sciences brings extensive experience in advanced therapy manufacturing facility design and optimization, having supported over 30 life science companies in implementing innovative solutions for complex manufacturing challenges.
The strategic partnership will support BioCentriq’s planned facility completion and operational readiness by Q2 2025. The enhanced facility will feature state-of-the-art capabilities for cell therapy development, manufacturing, and testing, supported by advanced digital systems and optimized operational workflows. This collaboration reflects a shared vision to advance cell therapy manufacturing, addressing growing market demands and driving innovation that supports the future of advanced therapies.